AAREYDRUGS · Aarey Drugs & Pharmaceuticals Limited · Financials
Volume · Nov 13
8394
Avg daily vol (3M)
10.22K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
4.72B
-0.4%
FY2026
Net Income
39.68M
-1.4%
FY2026
Operating Cash Flow
101.39M
+5%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| INR | 4.15B | 4.72B | 4.74B | 3.96B | 624.71M | 4.93B |
| INR | 32.15M | 28.53M | 19.45M | 16.98M | 7.1M | 19.88M |
| INR | 56.39M | 50.02M | 40.17M | 43.75M | 5.51M | 20M |
| INR | 42.01M | 54.14M | 61.02M | 53.43M | 7.46M | 100.27M |
| INR | 270K | 14.47M | 20.78M | 6.59M | 2.51M | 24.99M |
| INR | 41.74M | 39.68M | 40.24M | 46.84M | 4.95M | 75.28M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 0 in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.